Roche Holding Chart News Today

FDA Approves Genentech's Vabysmo for the Treatment of Retinal Vein Occlusion (RVO) Seite 1

October 27, 2023

27.10.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). RVO ... Seite 1

Genentech's Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer Seite 1

October 18, 2023

18.10.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the primary analysis of the Phase III ALINA study demonstrating a statistically significant and clinically meaningful improvement in disease-free ... Seite 1

Levi Garraway Roche Group European Society Of Medical Oncology Global Product Development Drug Administration Peter Maccallum Cancer Centre

Source: wallstreet-online.de

Navigation

Roche Holding Chart News Today

FDA Approves Genentech's Vabysmo for the Treatment of Retinal Vein Occlusion (RVO) Seite 1

Genentech's Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer Seite 1

Explore More Categories